CS Praza do Ferrol, EOXI Lugo, Cervo, e Monforte, Galician Health Service, Lugo, Spain.
School of Dentistry, University of Granada, Granada, Spain.
Oral Dis. 2022 Jan;28(1):57-65. doi: 10.1111/odi.13643. Epub 2020 Oct 5.
To identify the immunohistochemical pattern of non-tumoral epithelium adjacent to lip cancer (ANTE) to unveil molecular alterations and potential biomarkers in lip cancer patients.
A systematic search at MEDLINE, EMBASE and proceedings Web of Science, OpenGrey and WorldCat. The PICOS outline (Population: lip cancer patients; Intervention: immunostaining with biomarkers in surgical specimens; Comparisons: ANTE versus LC; Outcomes: primary-to identify the immunohistochemical pattern of peritumoral epithelium and secondary-to assess the immunoreactivity of LC epithelium; and Study design: cross-sectional, case-control and cohort studies).
A total of 339 records were identified. Seven studies reporting on ANTE and LCs were included in the qualitative synthesis, and 4 of them (p53 immunostaining) were selected for meta-analysis. In the ANTE group, the pooled prevalence of p53 was 0.74 (95% CI: 0.66 - 0.82), while in the lip squamous cell carcinoma group this prevalence was 0.83 (95% CI: 0.75 - 0.89).
Similar immunoexpression was found in lip epithelium adjacent to lip carcinoma, even in epithelia with normal appearance or mild histological alterations. The role of biomarkers in the follow-up of actinic cheilitis patients deserves additional clinical assessment.
确定唇癌（LC）旁非肿瘤上皮（ANTE）的免疫组织化学模式，以揭示唇癌患者的分子改变和潜在生物标志物。
在 MEDLINE、EMBASE 和 Web of Science 会议录、OpenGrey 和 WorldCat 进行系统检索。采用 PICOS 概述（人群：唇癌患者；干预措施：在手术标本中用生物标志物进行免疫染色；比较：ANTE 与 LC；结局：主要-确定肿瘤周围上皮的免疫组织化学模式，次要-评估 LC 上皮的免疫反应性；研究设计：横断面、病例对照和队列研究）。
共确定了 339 条记录。纳入了 7 项关于 ANTE 和 LCs 的研究进行定性综合分析，其中 4 项（p53 免疫染色）被选择进行荟萃分析。在 ANTE 组中，p53 的总患病率为 0.74（95%CI：0.66-0.82），而在唇鳞状细胞癌组中，这一患病率为 0.83（95%CI：0.75-0.89）。
即使在外观正常或组织学改变轻微的上皮中，也发现了与 LC 相邻的唇上皮相似的免疫表达。生物标志物在光化性唇炎患者随访中的作用值得进一步的临床评估。
